MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$31,260K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Sales and maturities of marketab...
Product revenue allowances
Accounts payable and other liabi...
Others
Negative Cash Flow Breakdown
Accounts receivable
Prepaid expenses and other asset...
Principal payments on finance le...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-62,513
-48,567
-141,187
-22,586
Depreciation of property and equipment
267
273
304
301
Stock-based compensation
2,107
2,563
2,285
2,112
Amortization of premiums and accretion of discounts on marketable securities
40
136
256
495
Loss on sales of marketable securities
-
-
0
-
Intangible asset amortization
1,987
1,987
1,752
1,752
Right-of-use asset amortization
1,451
1,267
3,807
-
Deferred income taxes
0
0
103,186
-5,974
Other non-cash adjustments, net
-490
-280
2,334
-1,390
Accounts receivable
2,802
2,333
4,075
5,569
Prepaid expenses and other assets
885
5,768
5,944
-703
Inventory
97
-294
1,280
-32
Accounts payable and other liabilities
10,204
1,480
9,077
-10,223
Product revenue allowances
18,761
-1,558
5,248
6,931
Net cash used in operating activities
-31,070
-50,218
-29,417
-31,626
Asset acquisition
-
-
0
0
Acquisition of intangible asset
0
10,000
-
-
Purchases of property and equipment
190
221
102
161
Purchases of marketable securities
0
0
2,032
14,047
Sales and maturities of marketable securities
34,000
30,455
47,000
35,570
Net cash provided by investing activities
33,810
20,234
44,866
21,362
Principal payments on finance leases
856
776
640
517
Tax obligations paid in connection with settlement of restricted stock units
0
0
0
0
Net cash used in financing activities
-856
-776
-640
-517
Effect of exchange rate changes on cash, cash equivalents and restricted cash
-36
-57
20
-180
Net change in cash, cash equivalents and restricted cash
1,848
-30,817
14,829
-10,961
Beginning of period
54,503
85,320
70,491
102,785
End of period
56,351
54,503
85,320
70,491
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Sales and maturities
of marketable...
$34,000K
(-72.94%↓ Y/Y)
Net cash provided by
investing activities
$33,810K
(18.08%↑ Y/Y)
Canceled cashflow
$190K
Net change in cash,
cash equivalents and...
$1,848K
(108.66%↑ Y/Y)
Canceled cashflow
$31,962K
Purchases of property and
equipment
$190K
(-74.15%↓ Y/Y)
Product revenue
allowances
$18,761K
(467.66%↑ Y/Y)
Accounts payable and
other liabilities
$10,204K
(-39.86%↓ Y/Y)
Stock-based compensation
$2,107K
(-58.50%↓ Y/Y)
Intangible asset
amortization
$1,987K
(-43.28%↓ Y/Y)
Right-of-use asset
amortization
$1,451K
Other non-cash
adjustments, net
-$490K
(83.03%↑ Y/Y)
Depreciation of property and
equipment
$267K
(-46.39%↓ Y/Y)
Net cash used in
operating activities
-$31,070K
(35.80%↑ Y/Y)
Net cash used in
financing activities
-$856K
(51.06%↑ Y/Y)
Effect of exchange rate
changes on cash, cash...
-$36K
(-119.67%↓ Y/Y)
Canceled cashflow
$35,267K
Net loss
-$62,513K
(-10.25%↓ Y/Y)
Principal payments on
finance leases
$856K
(2.64%↑ Y/Y)
Accounts receivable
$2,802K
(228.47%↑ Y/Y)
Prepaid expenses and
other assets
$885K
(-87.03%↓ Y/Y)
Inventory
$97K
(-95.63%↓ Y/Y)
Amortization of premiums and
accretion of discounts on...
$40K
(-96.93%↓ Y/Y)
Buy us a coffee
Vanda Pharmaceuticals Inc. (VNDA)
Vanda Pharmaceuticals Inc. (VNDA)